NASDAQ: GALT
Galectin Therapeutics Inc Stock Ownership - Who owns Galectin Therapeutics?

Insider buying vs selling

Have Galectin Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
James C. Czirr10% Owner2025-06-0625,000$4.72
$118.00kBuy
James C. Czirr10% Owner2025-06-0640,000$2.11
$84.40kBuy
James C. Czirr10% Owner2025-06-0630,000$2.86
$85.80kBuy
James C. Czirr10% Owner2025-06-0640,000$1.11
$44.40kBuy
James C. Czirr10% Owner2025-06-0670,000$2.11
$147.70kBuy
James C. Czirr10% Owner2025-06-0640,000$1.98
$79.20kBuy
James C. Czirr10% Owner2025-06-0631,250$0.89
$27.81kBuy
James C. Czirr10% Owner2025-06-0646,875$2.39
$112.03kBuy
James C. Czirr10% Owner2025-03-311,000$6.00
$6.00kBuy
Joel LewisPresident and CEO2025-03-0356,420$1.57
$88.58kSell

1 of 3

GALT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GALT insiders and whales buy or sell their stock.

GALT Shareholders

What type of owners hold Galectin Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
10x Fund LP40.69%25,751,845$35.28MInsider
James C. Czirr33.20%21,015,907$28.79MInsider
Rod D. Martin19.05%12,057,197$16.52MInsider
Richard E. Uihlein16.32%10,328,981$14.15MInsider
David Platt13.30%8,418,743$11.53MInsider
Vanguard Group Inc3.46%2,192,502$3.00MInstitution
Blackrock Inc2.24%1,414,911$1.94MInstitution
Osaic Holdings Inc1.93%1,223,416$1.68MInstitution
Geode Capital Management LLC1.35%852,706$1.17MInstitution
Geneos Wealth Management Inc1.34%850,670$1.17MInstitution

1 of 3

GALT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GALT11.50%88.50%Net BuyingNet Buying
ORMP19.02%51.76%
TCRX70.31%29.69%Net BuyingNet Buying
MIST22.12%24.01%
CLYM76.86%9.26%Net BuyingNet Selling

Galectin Therapeutics Stock Ownership FAQ

Who owns Galectin Therapeutics?

Galectin Therapeutics (NASDAQ: GALT) is owned by 16.31% institutional shareholders, 125.55% Galectin Therapeutics insiders, and 0.00% retail investors. 10x Fund LP is the largest individual Galectin Therapeutics shareholder, owning 25.75M shares representing 40.69% of the company. 10x Fund LP's Galectin Therapeutics shares are currently valued at $35.28M.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.